World Health Organization Issues Concern Over Severe Scarcity of Obesity Medications

Less than one in 10 patients that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it releases its first advice on the drugs.

Considering over a billion people worldwide now classified as obese, it is advocating for broader and more equitable access to these injectable treatments.

Per projections, over two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidelines recognises that obesity is a chronic disease that can be treated with thorough and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are significant obstacles to widespread availability to the jabs that can help people shift considerable body mass, notes the body.

Weight-Loss Drug Supply Crisis

Even under the present best projected case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.

The advice encourages countries and companies to expand availability, via approaches like voluntary licensing.

A patent on a key compound – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.

The Way Weight-Loss Jabs Operate

The injections mimick a biological compound to slow digestion, reduce hunger and increase feelings of fullness so users reduce food intake.

Individuals typically see weight reduction in the initial weeks of beginning the weekly injections.

Research suggests users may regain a significant portion after a year of discontinuing the treatment, because their typical appetite resume.

Being above a healthy weight increases your risk for developing health problems, such as diabetes, heart disease, stroke, and some cancers.

Excess weight concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, per the WHO.